Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
Epithelial ovarian cancer remains the leading cause of mortality among all gynecologic malignancies owing to recurrence and ultimate development of chemotherapy resistance in the majority of patients. In the chemotherapy-resistant ovarian cancer preclinical model, we investigated whether AZD6738 (an...
Main Authors: | Jin Hur, Mithun Ghosh, Tae Heon Kim, Nahee Park, Kamal Pandey, Young Bin Cho, Sa Deok Hong, Nar Bahadur Katuwal, Minsil Kang, Hee Jung An, Yong Wha Moon |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/3/1223 |
Similar Items
-
ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration
by: Guido Fròsina, et al.
Published: (2018-04-01) -
Synergistic effects of combining PARP inhibitor (AZD2281) and ATR inhibitor (AZD6738) in Ewing Sarcoma cell lines
by: Meyer, Stephanie C.
Published: (2018) -
ATM and ATR checkpoint kinase pathways: A concise review
by: Varsha Wagh, et al.
Published: (2020-01-01) -
Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status
by: Hind Hafsi, et al.
Published: (2018-07-01) -
Cancer cells with alternative lengthening of telomeres do not display a general hypersensitivity to ATR inhibition
by: Katharina I Deeg, et al.
Published: (2016-08-01)